/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT
|
|
- Andrew Black
- 5 years ago
- Views:
Transcription
1 原 著 , 2014 FIB4 Index FIB4 Index FIB4 Index cut off ,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index % FIB4 Index 5 FIB4 Index FIB4 Index 4AST AST/ ALT FIB4 Index AST FIB4 Index simple steatosis Sterling 1 AST ALT FIB4 IndexShah 2 high cut off FIB4 Index 1-4 FIB4 Index FIB4 Index FIB4 Index FIB4 Index Tel Fax ( 34 ) Vol.29 No
2 Shah 2 cut off 2.67 FIB4 Index ,059± 47.9± 9.5 9, ± 9.4 2, ±9.2 Sterling 1 FIB4 Index= AST IU/L /10 9 /L ALT IU/L 10 9 /L = 10 4 /mm 3 10 FIB4 Index FIB4 Index FIB4 Index 2.67 FIB4 Index AST ALT FIB4 Index 2.67 SPSS Statics18 IBM SPSS IBM Mann-WhitneyWilcoxon χ 2 p<0.05 1, ,213 1, , ,112 1,200 1,600 1 FIB4 Index 2 12,059 FIB4 Index 2.67 FIB4 Index 2.67 FIB4 Index 11, FIB4 Index Vol.29 No ( 35 )
3 2 n=12,059 FIB4 Index 3 Cut off 2.67 FIB4 Index FIB4 Index 0.99 FIB4 Index 1.91 FIB4 Index FIB4 Index FIB4 Index FIB4 Index FIB4 Index 47.8±9.4 FIB4 Index 58.5±9.8 p<0.001 FIB4 Index FIB4 Index ( 36 ) Vol.29 No
4 4 FIB4 Index cut off 2.67 FIB4 Index 2.67 / 1 FIB4 Index FIB4 Index 2.67 FIB4 Index 2.67 p % % p= % % 2 FIB4 Index FIB4 Index <2.67 FIB4 Index % % % % % % % % p N.S. N.S FIB4 Index 9,373 2,686 FIB4 Index 2 FIB4 Index161FIB4 Index 4AST ALT 4 AST AST/ALT AST/ALT 3 FIB4 Index Vol.29 No ( 37 )
5 3 FIB4 Index 2.67 Index (n = % AST IU/L % ALT IU/L % AST/ALT / μ L % 5 Non Alcoholic Fatty Liver Disease NAFLD Non Alcoholic Steatohepatitis NASH CT 1,7-13 Sterling 1 HIV HCV FIB4 Index Shah 2 NAFLD NAFLD Fibrosis Score ROC high cut off low cut off Yang 3 Sumida 4 FIB4 Index 7FIB4 Index ROC FIB4 Index 6 8 FIB4 Index FIB4 Index 1.3 FIB4 Index98.7 AST ALT FIB4 Index FIB4 IndexFIB4 Index FIB4 Index FIB4 Index FIB4 Index58.5 FIB4 Index FIB4 Index FIB4 Index 5 5 FIB4 Index FIB4 Index FIB4 Index 5 10 FIB4 Index FIB4 Index AST ALT 38 ( 38 ) Vol.29 No
6 AST AST/ALT 0.86 ALT 1.18 AST AST 5 NAFLD AST ALT NASH AST/ALT 14 AST FIB4 Index AST FIB4 Index 15 FIB4 Index FIB4 Index161 3 X CT 16 FIB4 Index FIB4 Index cut off 2.67 cut off FIB4 Index cut off Fujii 17 FIB4 Index BMIHarrison 11 BARD score BMI 18 BMI FIB4 IndexBMI cut off 12,059 9, FIB4 Index FIB4 Index Sterling 1 high cut off 3.25 Sumida 4 NAFLD FIB4 Index Sterling 3.25 Shah cut off cut off 3.25 FIB4 Index FIB4 Index cut off Vol.29 No ( 39 )
7 20 FIB4 Index FIB4 Index AST Sterling RK, Lissen E, Clumeck N, et al: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: Shah AG, Lydecker A, Murray K, et al: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: Yang HR, Kim HR, Kim MJ, et al: Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18: Sumida Y, Yoneda M, Hyogo H, et al: Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: : 4. NAFLD. NASH NAFLD Poynard T, Bedossa P: Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4: Ratziu V, Giral P, Charlotte F, et al: Liver fibrosis in overweight patients. Gastroenterology 2000; 118: Wai CT, Greenson JK, Fontana RJ, et al: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: Angulo P, Hui JM, Marchesini G, et al: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: Harrison SA, Oliver D, Arnold HL, et al: Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: Miyaaki H, Ichikawa T, Nakao K, et al: Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008; 28: Sumida Y, Yoneda M, Hyogo H, et al: A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: NAFLD NASH NAFLD Fujii H, Enomoto M, Fukushima W, et al: Applicability of BARD score to Japanese patients with NAFLD. Gut 2009; 58: NAFLD update Yoneda M, Yoneda M, Mawatari H, et al: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: ( 40 ) Vol.29 No
8 Time-dependent Changes in FIB4 Index in Patients with Fatty Liver Disease Nobuyuki Kobayashi 1), Takashi Tsuzuki 1), Tomoko Manzoji 1), Hiroyuki Watabe 1), Miyoko Takezawa 2), Atsushi Tsuchiya 1), Akira Tsuchiya 1) 1) Sagamihara health evaluation and promotion center 2) Department of Gastroenterology, Kitasato University School of Medicine Abstract Objective: To examine the effectiveness of the FIB4 index as an indicator of fibrosis in fatty liver. Methods: In fatty liver patients examined several times, we calculated the FIB4 index for the initial and final examinations. Taking the cutoff point for fibrosis as 2.67, 12,059 individuals in whom the index was less than 2.67 were enrolled as the subjects of this study. The change in the FIB4 index during the period from the initial to the final examination was determined. For subjects in whom the FIB4 index had risen to 2.67 or over at the final examination, we made comparisons by gender as well as by whether the fatty liver was alcoholic or non-alcoholic. We analyzed changes in the factors of the FIB4 calculation formula (age, AST, ALT, platelet counts) as well as those in ultrasonography images. Results: The FIB4 index had risen to 2.67 or above in 161 subjects (1.3%) at the final examination and in these subjects it was significantly higher than at the initial examination. There had been an increase in FIB4 index in 1.1% of subjects followed up for less than 5 years, whereas FIB4 index had increased in 1.6% of those followed up for 5 years or more and the difference between these groups was significant. There were no differences in frequencies of rises in FIB4 index between males and females or between alcoholic and non-alcoholic fatty livers. Regarding the 4 factors of the FIB4 index calculation formula, the biggest change was in AST, with the AST/ALT ratio increasing from 0.86 at the initial examination to 1.18 at the final examination. The only change in ultrasonography images observed was dullness of the hepatic margin in 3 of the 161 subjects. Conclusion: The length of time required for changes in the FIB4 index and the greater change in AST suggest that it could be used as a predictive index of fibrosis. Keywords: FIB4 Index, fatty liver disease, nonalcoholic fatty liver disease (NAFLD), liver fibrosis Vol.29 No ( 41 )
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More informationBackground of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease
ORIGINAL ARTICLE Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease Takashi Wada and Mikio Zeniya Abstract Objective We investigated the distribution and characteristics of the
More informationSimple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
1 Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle upon Tyne, UK 2 Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne,
More informationNew discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan
Hepatol Int (215) 9:269 277 DOI 1.17/s1272-14-965-x ORIGINAL ARTICLE New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan Yusuke Kawamura Kenji Ikeda Yasuji Arase
More informationSimple Tests to Predict Hepatic Fibrosis in Nonalcoholic Chronic Liver Diseases
Gut and Liver, Vol. 1, No. 2, December 2007, pp. 145-150 original article Simple Tests to Predict Hepatic Fibrosis in Nonalcoholic Chronic Liver Diseases Woon Geon Shin*, Sang Hoon Park*, Sun-Young Jun,
More informationScreening cardiac patients for advanced liver disease
HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationBio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis
AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using
More informationThe classical metabolic work-up, approved by the Ethics Committee of the Antwerp
SUPPLEMENTARY MATERIALS METHODS Metabolic work-up The classical metabolic work-up, approved by the Ethics Committee of the Antwerp University Hospital and requiring written informed consent, included a
More informationSerum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty
Supplementary Information Serum YKL- as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease Erina Kumagai 1,,#, Yohei Mano 1,#, Sachiyo Yoshio 1, Hirotaka Shoji 1, Masaya Sugiyama
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationPROGRESSION TO FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) THE VALUE OF NONINVASIVE MARKERS
Supplement 1/2015, 4 th ISAA PROGRESSION TO FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) THE VALUE OF NONINVASIVE MARKERS Denisa DOBRIN 1, Tiberiu Ioan NANEA 2, Cristian Mihai POMOHACI
More informationBio Predictive. FibroTest Scientific Publications. Ratziu 2016 FibroMax NASH. Friedman 2016 FibroTest NASH EASL Key Publications for 2017
EASL 2017 Scientific Publications Ratziu 2016 NASH Friedman 2016 NASH SteatoTest and sensitive markers of improvement in NASH trial using Elafibranor Elafibranor, an agonist of the peroxisome proliferator
More informationComparison between FIB-4 Index and Fibroscan as Marker of Fibrosis in Chronic HCV Infection in Egyptian Patients
Open Journal of Gastroenterology, 2014, 4, 383-391 Published Online December 2014 in SciRes. http://www.scirp.org/journal/ojgas http://dx.doi.org/10.4236/ojgas.2014.412052 Comparison between FIB-4 Index
More informationWith the advent of highly active antiretroviral therapy
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:1070 1076 Similar Progression of Fibrosis Between HIV/HCV Infected and HCV Infected Patients: Analysis of Paired Liver Biopsy Samples RICHARD K. STERLING,*,
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationInt J Clin Exp Med 2016;9(2): /ISSN: /IJCEM
Int J Clin Exp Med 2016;9(2):3687-3692 www.ijcem.com /ISSN:1940-5901/IJCEM0014273 Original Article Diagnostic value of transient elastography combined with noninvasive scores for the detection of advanced
More informationNonalcoholic fatty liver disease (NAFLD) and nonalcoholic. Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1162 1168 Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients SVEN M. A. FRANCQUE,* AN VERRIJKEN, ILSE MERTENS, GUY
More informationNew Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease
ORIGINAL ARTICLE New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease Yusuke Kawamura 1,2, Kenji Ikeda 1,2, Yasuji Arase 1,2, Shunichiro Fujiyama
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationCASE REPORT. Introduction. Case Report
doi: 10.2169/internalmedicine.8754-16 Intern Med Advance Publication http://internmed.jp CASE REPORT The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationManaging abnormal LFTs in Primary care
Managing abnormal LFTs in Primary care Summary guideline, April 2015 Sally Hull, Lucy Carter Managing abnormal LFTs in Primary care Draft guideline written by Dr Sally Hull and Dr Lucy Carter at CEG, with
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationREVIEWS. Introduction. FibroMax complete diagnosis of liver injury. Abbreviations
REVIEWS Noninvasive Biomarkers for the Screening of Fibrosis, Steatosis and Steatohepatitis in Patients with Metabolic Risk Factors: FibroTest-FibroMa Eperience Mona Munteanu, Vlad Ratziu 2, Rachel Morra,
More informationNonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup
REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Varun Saxena, MD MAS Gastroenterology and Hepatology Kaiser Permanente South San Francisco Assistant Clinical Professor University of California San Francisco January
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationAssessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationSignificance of Hepatic Insulin Clearance in Patients with Chronic Hepatitis C and Non-alcoholic Fatty Liver Disease
ORIGINAL ARTICLE Significance of Hepatic Insulin Clearance in Patients with Chronic Hepatitis C and Non-alcoholic Fatty Liver Disease Hisamitsu Miyaaki 1, Tatsuki Ichikawa 1,NaotaTaura 1, Satoshi Miuma
More informationNAFLD: US GUIDELINES. US Guidelines for NAFLD
NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG
More informationCase #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis
45 year old woman presented with abnormal liver function tests Liver Biopsy to r/o autoimmune hepatitis Further down. ANA 1: 160; ASMA 1:80 ANA 1: 160; ASMA 1:80 IgG = 14.5 g/l (upper normal range: 16)
More informationClinical Case. Ana Carolina Cardoso, MD Federal University of Rio de Janeiro - Brazil
Clinical Case Ana Carolina Cardoso, MD Federal University of Rio de Janeiro - Brazil Disclosures Nothing to declare - A 55-year-old female, asymptomatic, underwent abdominal ultrasound that revealed severe
More informationFatty Liver in HIV. Richard K. Sterling, MD, MSc, FACP, FACG
Fatty Liver in HIV Richard K. Sterling, MD, MSc, FACP, FACG Professor of Medicine Chief, Section of Hepatology Director, HIV-Liver Disease Virginia Commonwealth University Liver-Related Deaths in HIV 1246
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More informationDevelopment and validation of a simple index system to predict nonalcoholic fatty liver disease
The Korean Journal of Hepatology 2011;17:19-26 DOI: 10.3350/kjhep.2011.17.1.19 Original Article Development and validation of a simple index system to predict nonalcoholic fatty liver disease Young Jin
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Harris R, Harman DJ, Card TR, Aithal GP, Guha
More informationAtanasova, Evelina 1, Martinova, Fani 2, Jelev, Deyan 1, Antonov, Krassimir 1, de Mey, Christian 3,Mateva, Ludmila 1, Krastev, Zahary 1.
Alpha-2 macroglobulin is the simplest serum biomarker for liver fibrosis and fibrogenesis in chronic hepatitis C Atanasova, Evelina 1, Martinova, Fani 2, Jelev, Deyan 1, Antonov, Krassimir 1, de Mey, Christian
More informationCASE REPORT. Introduction. Case Report
doi: 10.2169/internalmedicine.8754-16 Intern Med 56: 2739-2744, 2017 http://internmed.jp CASE REPORT The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis
More informationWhat to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology
What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy
More informationtage Percent Total & over Total & over Men Women Men Women
Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University
More informationA practical clinical approach to liver fibrosis
Singapore Med J 2018; 59(12): 628-633 https://doi.org/10.11622/smedj.2018145 CMEArticle A practical clinical approach to liver fibrosis Rahul Kumar 1, MBBS, MRCP, Eng Kiong Teo 1, MBBS MRCP, How Choon
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationORIGINAL ARTICLE. Both these authors contributed equally to this study. Liver International ISSN
Liver International ISSN 1478-3223 ORIGINAL ARTICLE The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients
More informationWhen to Treat: Staging Liver Disease David L. Thomas, MD, MPH
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationUnderstanding your FibroScan Results
PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationNASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014
NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationAASLD Immune tolerant phase HBV NAFLD diagnostic HCC
AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY
More informationResearch Article. Gastroenterology & Hepatology Journal (GHJ) Introduction. Abstract
Gastroenterology & Hepatology Journal (GHJ) Research Article Study of Some Serum Biochemical Markers of Liver Fibrosis in Patients with Chronic HCV Aly M EL-Kady 1, Hossam EL-Din F Abo El-Kheir 1, Abeer
More informationComparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1104 1112 Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease AMY G. SHAH,* ALISON LYDECKER, KAREN MURRAY, BRENT
More informationPractical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review
Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review Authors: Jennifer Gallacher, 1 *Stuart McPherson 1,2 1. Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman
More informationHepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan
Akuta et al. BMC Gastroenterology (2018) 18:165 https://doi.org/10.1186/s12876-018-0900-1 RESEARCH ARTICLE Open Access Hepatocellular carcinoma is the most common liver-related complication in patients
More informationThe diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients
1130-0108/2015/107/12/740-744 Revista Española de Enfermedades Digestivas Copyright 2015 Arán Ediciones, S. L. Rev Esp Enferm Dig (Madrid) Vol. 107, N.º 12, pp. 740-744, 2015 ORIGINAL PAPERS The diagnostic
More informationEvaluating Obese Persons With Abnormal Liver Chemistries
Mary E. Rinella, MD, FAASLD Evaluating Obese Persons With Abnormal Liver Chemistries Postgraduate Course: Challenges in Management of Common Liver Diseases 275 1 25 year old obese Hispanic man with obesity,
More informationNAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
More informationLiver 102: Injury and Healing
Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns
More informationOriginal article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients
Antiviral Therapy 2011; 16:165 172 (doi: 10.3851/IMP1726) Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients Grace Lai-Hung Wong 1,2,
More informationInvestigating general liver disease/transaminitis
BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationSection: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013
Medical Policy Manual Topic: Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Date of Origin: June 2013 Section: Laboratory Last Reviewed
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011
HCC Prevention Jee-Fu Huang Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan TCC, HCC Prevention, 26 Nov, 2011 1 Outline Pathogenic and Risk Factors HBV HCV Primary Secondary Primary
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION
SL 2-1 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION Mikio KAJIHARA 1,3, Yoshinori HORIE 2,3, Hiromasa ISHII 3 1 Tokyu Hospital, 2 Eiju General
More informationCorrelation between bright echogenic liver, elevated liver enzymes and liver histology.
Original Article Correlation between bright echogenic liver, elevated liver enzymes and liver histology. Dr. Iqbal Murshed Kabir, Dr. Mahbub Alam, Dr. Mohammad Mahmuduzzaman, Dr. Abdullah Al Mamoon, Dr.
More informationTransient elastography in chronic viral liver diseases
4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique
More informationObesity, metabolic syndrome (MetS), and type 2 diabetes
Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD Naim Alkhouri, MD, and Arthur J. McCullough, MD Dr. Alkhouri and Dr. McCullough are affiliated with the Department of Gastroenterology
More informationI N Guha, J Parkes, P R Roderick, S Harris, W M Rosenberg
1650 Recent advances in clinical practice NON-INVASIVE MARKERS ASSOCIATED WITH LIVER FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE See end of article for authors affiliations Correspondence to: Dr I N
More informationLiver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients
Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients José Vicente Fernández-Montero, Pablo Barreiro, Eugenia Vispo, Pablo Labarga, Francisco Blanco, Fernanda Rick,
More informationThe Efficacy of Corticosteroid Therapy in a Patient with Nonalcoholic Steatohepatitis Overlapping Autoimmune Hepatitis: A Case Report
doi: 10.2169/internalmedicine.8887-17 Intern Med Advance Publication http://internmed.jp CASE REPORT The Efficacy of Corticosteroid Therapy in a Patient with Nonalcoholic Steatohepatitis Overlapping Autoimmune
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationIS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE?
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 3 INTERNAL MEDICINE - PEDIATRICS UPDATES IS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE? R. S. Gavril 1, Laura Mihalache
More informationA Combination of the Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis Test Identifies Children With Fibrosis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:150 155 A Combination of the Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis Test Identifies Children With Fibrosis NAIM ALKHOURI,* CHRISTINE
More informationReal-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study
ORIGINAL ARTICLE Annals of Gastroenterology (2016) 29, 1-5 Real-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study Lamiaa Mobarak
More informationALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,
Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total
More informationChallenges in the Diagnosis of Steatohepatitis
The Bugaboos of Fatty Liver Disease: Ballooning and Fibrosis Hans Popper Hepatopathology Society Companion Meeting San Antonio, Tx March, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Challenges
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationHEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS
HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS Essam A. Wahab*, Talaat Fathy** Sameh Saber*** and Hanan S. Ahmad**** Internal Medicine*,
More informationA Modification of the Brunt System for Scoring Liver Histology of Patients with Non-Alcoholic Fatty Liver Disease
Arch Iran Med 2010; 13 (1): 38 44 Original Article A Modification of the Brunt System for Scoring Liver Histology of Patients with Non-Alcoholic Fatty Liver Disease Shahin Merat MD*, Farzaneh Khadem-Sameni
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationABSTRACT INTRODUCTION. Qiang Li 1,2, Chuan Lu 1, Weixia Li 1, Yuxian Huang 1,2, Liang Chen 1. Research Paper
/, 2017, Vol. 8, (No. 17), pp: 28641-28649 The gamma-glutamyl transpeptidase to platelet ratio for noninvasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty
More informationNon-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know
Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
More informationThe predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C
The predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C LIVER Hale Gökcan 1, Ufuk Barış Kuzu 1, Erkin Öztaş 1, Fatih Saygılı 1, Derya Öztuna 2, Nuretdin
More informationBariatric Surgery and Liver Transplantation
Bariatric Surgery and Liver Transplantation Sammy Saab, MD, MPH, AGAF, FACG, FAASLD Professor of Medicine and Surgery Head, Outcomes Research in Hepatology David Geffen School of Medicine at UCLA Disclosures
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationPreliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity
Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity Dr. Katsutoshi Sugimoto Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan Introduction
More informationNovel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,
More information